1. Home
  2. GH vs TMDX Comparison

GH vs TMDX Comparison

Compare GH & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

N/A

Current Price

$84.39

Market Cap

13.3B

Sector

Health Care

ML Signal

N/A

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

N/A

Current Price

$122.21

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GH
TMDX
Founded
2011
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3B
4.6B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
GH
TMDX
Price
$84.39
$122.21
Analyst Decision
Strong Buy
Buy
Analyst Count
20
9
Target Price
$117.80
$154.00
AVG Volume (30 Days)
1.6M
791.1K
Earning Date
05-11-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
6.74
382.18
EPS
N/A
4.87
Revenue
$982,021,000.00
$605,494,000.00
Revenue This Year
$33.40
$24.12
Revenue Next Year
$28.55
$18.69
P/E Ratio
N/A
$26.48
Revenue Growth
32.88
37.13
52 Week Low
$36.36
$62.42
52 Week High
$120.74
$156.00

Technical Indicators

Market Signals
Indicator
GH
TMDX
Relative Strength Index (RSI) 27.18 37.25
Support Level $54.39 $106.27
Resistance Level $114.53 $128.96
Average True Range (ATR) 4.54 8.92
MACD -0.83 -1.85
Stochastic Oscillator 10.30 2.52

Price Performance

Historical Comparison
GH
TMDX

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: